[197 Pages Report] The Plasma Fractionation Market size was estimated at USD 35.52 billion in 2023 and expected to reach USD 38.95 billion in 2024, at a CAGR 10.45% to reach USD 71.27 billion by 2030.
Plasma fractionation refers to collecting, separating, and purifying various essential components present in human plasma, primarily including albumin, immunoglobulins, coagulation factors, and other proteins. These components have many applications in medical treatments, such as hemophilia therapy, immunity disorders treatment, wound healing support, neurology therapy, and other rare diseases. The demand for source plasma has been steadily increasing due to its role as a vital ingredient in several life-saving therapies. This surge can be attributed to an aging population prone to chronic illnesses requiring blood-based therapies and the rising prevalence of immune disorders. In addition, rising awareness about blood-related diseases among patients contributes significantly to this market's expansion. However, stringent government regulations on plasma fractionation and the presence of alternative recombinant therapies may hamper the market demand. New advancements in production technology further boost opportunities for the players involved in this field. Moreover, strategic collaborations among various stakeholders drive innovative research work within the industry that provides novel solutions and is expected to create a lucrative market opportunity in the forecasted period.
The Americas has a significant market presence in the plasma fractionation market due to a well-established healthcare infrastructure, high prevalence of immunodeficiency diseases, and an increasing geriatric population. In Europe, EU countries have a strong regulatory framework governing the plasma fractionation industry. The European Medicines Agency (EMA) regulates manufacturing practices and oversees quality standards for blood-derived products, significantly driving the region's market demand. The MEA region presents lucrative opportunities due to rising incomes and expanding access to healthcare services. The Asia-Pacific observed a developing landscape in the plasma fractionation market owing to rapid urbanization and economic development that is driving investments in healthcare infrastructure. Additionally, there is an increasing focus on blood safety regulations by governments in the APAC region, presenting opportunities for market players.
Albumin is a major plasma protein critical in regulating blood volume and transporting various substances, including hormones, drugs, and nutrients. It primarily treats hypovolemia (low blood volume), hypoalbuminemia (low albumin levels), and severe burns. Coagulation factor concentrates are essential for treating bleeding disorders such as hemophilia A & B and von Willebrand disease and replace missing or deficient clotting factors, preventing excessive bleeding and promoting proper wound healing. Immunoglobulins are antibodies that play a crucial role in the body's immune response by neutralizing pathogens such as bacteria and viruses and are used to treat primary immunodeficiency diseases, inflammatory and autoimmune disorders, and certain types of cancer. Protease inhibitors are essential for managing hereditary angioedema (HAE), a periodic genetic condition characterized by recurrent episodes of severe swelling in various body parts. These inhibitors block the action of proteases responsible for inflammation and vascular permeability during hereditary angioedema (HAE) attacks.
In the critical care setting, plasma fractionation products are vital for treating life-threatening conditions such as sepsis, burns, and trauma. Plasma fractionation has significant applications in hemato-oncology for managing blood-related cancers and supporting chemotherapy treatments. Hematology involves the prevention, diagnosis, and treatment of blood diseases such as hemophilia or von Willebrand disease (VWD). Plasma fractionation products including IVIG are increasingly used in treating neurological conditions, including Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), and multiple sclerosis. In pulmonology, plasma fractionation helps in managing respiratory diseases such as alpha-1 antitrypsin deficiency (AATD) and acute respiratory distress syndrome (ARDS). Plasma fractionation is utilized in rheumatology primarily through the use of IVIG to manage autoimmune and inflammatory disorders.
Academic & research institutes are engaged in basic research to advance the understanding of plasma proteins and their therapeutic potential. The key needs for this segment include high-purity plasma fractions for protein characterization studies, advanced fractionation techniques that can lead to discoveries, and access to reliable sources of raw material. Clinical research laboratories are essential for testing and validating plasma fractionation processes and products. They conduct trials to ensure the safety and efficacy of plasma-derived products, assess their impact on patients, and gather data to support regulatory approval. These laboratories are involved in both pre-clinical and clinical stages of product development.
The market dynamics represent an ever-changing landscape of the Plasma Fractionation Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Plasma Fractionation Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Plasma Fractionation Market.
The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Plasma Fractionation Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.
The value chain of the Plasma Fractionation Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.
The pricing analysis comprehensively evaluates how a product or service is priced within the Plasma Fractionation Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Plasma Fractionation Market.
The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Plasma Fractionation Market.
The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Plasma Fractionation Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.
The trade analysis of the Plasma Fractionation Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.
The regulatory framework analysis for the Plasma Fractionation Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Plasma Fractionation Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Plasma Fractionation Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Grifols Egypt delivers first plasma medicines made from Egyptian plasma donations
Grifols, a producer of plasma-derived medicines, has partnered with Egypt's National Service Projects Organization (NSPO) to inaugurate their first plasma-derived medicines. These medicines are manufactured using donations from Egypt, ensuring a reliable and sustainable source. The shipment includes vital plasma therapies such as albumin, which is utilized in major surgeries, trauma treatment, and severe burn cases. Additionally, immunoglobulins (Ig) are included for immunodeficiencies, along with blood-clotting factors to manage bleeding disorders. [Published On: 2023-06-07]
CSL's USD470 Million Plasma Fractionation Facility Opens in Marburg, Germany
CSL, a biotechnology company, recently celebrated the inauguration of its state-of-the-art plasma fractionation facility in Marburg, Germany. This monumental project, with a budget of USD 470 million, spanned five years and has quadrupled the company's manufacturing capacity for producing life-saving medicines derived from donated human plasma. The new facility, leveraging optimized process flows, cutting-edge technologies, and advanced automation, has significantly enhanced operational efficiency. [Published On: 2023-03-24]
Takeda to Invest 100 Billion JPY in a New Manufacturing Facility for Plasma-Derived Therapies in Japan
Takeda is making a significant investment of approximately 100 billion yen to construct a state-of-the-art manufacturing facility in Osaka, Japan. This facility is expected to be the largest and specialized in the production of plasma-derived therapies in the country. The investment aligns with Takeda's capital allocation policy, which aims to create value and establish a world-class end-to-end manufacturing facility for PDTs at its Juso, Osaka plant. [Published On: 2023-03-23]
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Plasma Fractionation Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
The report delves into recent significant developments in the Plasma Fractionation Market, highlighting leading vendors and their innovative profiles. These include 3M Company, ADMA Biologics, Inc., Bharat Serums and Vaccines Limited, Bio Products Laboratory Ltd., Biotest AG by Grifols, S.A., China Biologic Products, Inc., CSL Limited, Emergent BioSolutions Inc., Fusion Health Care Pvt. Ltd., GC Biopharma corp., Grifols, S.A., HEINKEL Process Technology GmbH, Hemarus Therapeutics Ltd, Intas Pharmaceuticals Ltd., Kamada Ltd., Kedrion S.p.A., LFB SA, Merck KGaA, Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., Prothya Biosolutions B.V., Sanquin, Shanghai Raas Blood Products Co. Ltd, SK Plasma Co.,Ltd., STERIS plc, and Takeda Pharmaceutical Company Ltd.
This research report categorizes the Plasma Fractionation Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Product
- Albumin
- Coagulation Factor Concentrates
- Factor IX
- Factor VIII
- Factor XIII
- Fibrinogen Concentrates
- Prothrombin Complex Concentrate
- Von Willebrand Factor
- Immunoglobulin
- Intravenous Immunoglobulin
- Subcutaneous Immunoglobulin
- Protease Inhibitors
- Application
- Critical Care
- Hemato-Oncology
- Hematology
- Neurology
- Pulmonology
- Rheumatology
- End-User
- Academic & Research Institutes
- Clinical Research Laboratories
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
- Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
- Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
- Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
- Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
- Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.
- What is the current market size and projected growth?
- Which products, segments, applications, and regions offer promising investment opportunities?
- What are the prevailing technology trends and regulatory frameworks?
- What is the market share and positioning of the leading vendors?
- What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?
- Preface
- Research Methodology
- Executive Summary
- Market Overview
- Market Insights
- Plasma Fractionation Market, by Product
- Plasma Fractionation Market, by Application
- Plasma Fractionation Market, by End-User
- Americas Plasma Fractionation Market
- Asia-Pacific Plasma Fractionation Market
- Europe, Middle East & Africa Plasma Fractionation Market
- Competitive Landscape
- Competitive Portfolio
- List of Figures [Total: 22]
- List of Tables [Total: 476]
- List of Companies Mentioned [Total: 26]
Benefits of Plasma Fractionation:
Plasma is the fluid part of the blood that carries vital proteins and other nutrients throughout the body. Plasma fractionation separates plasma into different fractions, allowing the extraction of useful constituents such as albumin, immunoglobulin, and clotting factors. These fractions can be used to make medications for a range of medical conditions, such as immune deficiencies, hemophilia, and viral infections. The extracted proteins and other blood components are crucial in managing bleeding disorders, preventing infections, and fighting autoimmune diseases.
Plasma Fractionation Process:
The process of plasma fractionation is complex and involves several steps. The first step is to collect blood from donors at a blood donation center or hospital. Next, the blood is collected in a blood bank and tested for infectious agents such as Hepatitis B, C, and HIV. After screening, the plasma is separated from the other blood cells and subjected to a process that breaks it down into its components. The extracted proteins undergo rigorous quality testing to ensure their safety and efficacy. They are then packaged in vials or syringes and shipped to healthcare facilities worldwide.
Impact on the Elderly:
Aging causes several physiological changes that make elderly people more vulnerable to infections, chronic diseases, and blood clotting disorders. The plasma-derived products help in managing these conditions, and they are widely prescribed to elderly patients.
The Future of Plasma Fractionation:
Research in plasma fractionation has shown a promising future for the industry. The development of new technologies, such as nucleic acid-based testing, has improved blood safety and reduced the risk of infectious transmission. The industry is also looking towards the development of new products such as anti-cancer immunotherapies and new clotting factors. Advances in technology and distribution channels have made plasma fractionation drugs more accessible to people around the world.
Plasma fractionation is a vital process that has been improving lives for decades. The significance of plasma-derived products has increased with the rise of the elderly population and the increasing number of blood collection facilities. Plasma-derived products play a key role in the management of diseases like coagulation disorders, immune deficiencies, and infections. The rise of new technologies and research in the field bodes well for the future and will ensure that plasma-derived products continue to improve the quality of life for people around the globe.
- How big is the Plasma Fractionation Market?
- What is the Plasma Fractionation Market growth?
- When do I get the report?
- In what format does this report get delivered to me?
- How long has 360iResearch been around?
- What if I have a question about your reports?
- Can I share this report with my team?
- Can I use your research in my presentation?